European cannabis products have been more popular than expected
At Pharmadrug, we believe the boon in European medical cannabis is in its infancy. In fact, a recent Davos report predicts that the E.U. will be the largest medical cannabis market in five years, totaling nearly 60 billion Euros.
While nearly all small cap marijuana companies are set on growing their businesses in the Canadian and U.S. markets, management at Pharmadrug has a much different approach. Our focus is on building a vertically-integrated business for medical marijuana in the European Union. While Pharmadrug may be a little early to the European cannabis party, we are confident we will be able to generate significant shareholder value in the long run as equity markets begin to see the value in Europe.
Also, you can always view the Pharmadrug stock quote here: CSE:BUZZ